Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs f…
Biotechnology
US, Cranbury [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | 34.31 | 10.47 | 7.80 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | -73.43 | 0.14 | 0.54 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | -10.57 | 4.72 | 5.28 | |
| Cash | -11.69 | 3.53 | 4.00 | |
| Capex | 56.31 | -0.02 | -0.05 | |
| Free Cash Flow | -72.96 | -0.63 | -0.36 | |
| Revenue | inf | 0.00 | 0.11 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | inf | 0.00 | 0.50 | |
| Operating Margin | inf | 0.00 | -6.14 | |
| ROA | -17.94 | -0.12 | -0.11 | |
| ROE | -16.04 | -0.14 | -0.12 | |
| ROIC | -14.77 | -0.14 | -0.13 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of RCKT is permitted for members.
5
Growth
The "Growth Entry" for the Focus of RCKT is permitted for members.
6
Leverage & Liquidity